RoosterBio Announces Plans to Expand Facility in Frederick, MD

Share Article

Growth fueled by advancements in global regenerative medicine market

News Image
“The additional expansion space in the building we already occupy at The Offices at Westview will better accommodate our growing staff and support our company’s vision.” - Margot S. Connor, CEO, RoosterBio

RoosterBio, Inc, a privately held regenerative medicine manufacturing platform technology company announced plans today to expand the company’s footprint in Frederick, MD after a year of rapid growth.

“Hundreds of researchers and scientists around the world have used RoosterBio’s adult human mesenchymal stem/stromal cell (hMSCs) products to streamline their product development efforts in the regenerative medicine field, resulting in strong growth for our company,” said RoosterBio CEO Margot S. Connor. “The additional expansion space in the building we already occupy at The Offices at Westview will better accommodate our growing staff and support our company’s vision.”

Founded in 2013, RoosterBio, Inc. launched operations inside of the Frederick Innovative Technology Center, Inc (FITCI) incubator with five people. In February 2018, the company held a ribbon cutting for their custom-built 14,000 square foot facility designed to accommodate innovation in scale up of mesenchymal cell manufacturing, research and development. In January 2019, the company grew to more than 40 employees and plans to double again in the next 18-24 months.

RoosterBio has been actively shaping the new field of Regenerative Medicine Manufacturing with a diverse team of technology disruptors and thought leaders. The “off-the-shelf” cell banks and bioprocess media products that RoosterBio has commercialized are designed to remove years of time, and millions of dollars, from traditional mesenchymal cell therapeutic product development efforts. In 2018, RoosterBio launched its first line of cGMP-grade hMSC products that are capable of being directly used as starting materials within clinical manufacturing processes. As a premier cell manufacturing platform technology provider with over 50 products available and six additional product launches planned for 2019, RoosterBio aims to have the same impact on the emerging stem cell therapy & regenerative medicine fields that Intel had on the computer industry.

Serving more than 200 customers in 18 countries, RoosterBio has a corporate focus in 2019 to expand even further into the global market.

About RoosterBio, Inc.
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tom Curtis, Director of Marketing
Visit website